PCSK9:a new therapeutic target for cardiovascular calcification?

Home > Archive>Volume 32, Issue 9, 2024 >798-804

PCSK9:a new therapeutic target for cardiovascular calcification?
DOI:
                        
                    
CSTR:
                        [cstr]
                    
Author:
                        GONG XiGONG Xi
Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
XIANG QiongXIANG Qiong
Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
CHEN YanyuCHEN Yanyu
Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
TANG ZhihanTANG Zhihan
Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
PENG JuanPENG Juan
Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Institute of Cardiovascular Disease & Key Laboratory for Arteriosclerology of Hunan Province & Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang, Hunan 421001, China)
Clc Number:R5
Fund Project:

Article

Figures

Metrics

Reference

Cited by

Materials

Comments

Abstract:

Proprotein convertase subtilisin/kexin type 9 (PCSK9) comprised of 692 amino acids is the ninth member of protease family. It binds to the low-density lipoprotein receptor(LDLR), leading to elevated levels of circulating low-density lipoprotein cholesterol(LDLC), which can lead to a number of cardiovascular diseases, and among then the relationship with cardiovascular calcification has recently received attention. Cardiovascular calcification is a kind of ectopic mineralisation in the cardiovascular system, which is mainly characterised by the production of mineral deposits in the vascular wall and vascular valves, and its pathogenesis is related to lipoprotein content, platelet activity, matrix vesicle (MV) release and inflammation, through which PCSK9 may be involved in the occurrence of cardiovascular calcification.Therefore, this article reviews the relationship between PCSK9 and cardiovascular calcification, emphasizing the specific role of PCSK9 in affecting cardiovascular calcification through various pathways, assisting in setting up emerging applications of PCSK9 amid vessel biological science and recognize innovative molecular mechanisms for its treatment.

Key words:proprotein convertase subtilisin/kexin type 9; cardiovascular calcification; inflammation

Get Citation

GONG Xi, XIANG Qiong, CHEN Yanyu, TANG Zhihan, PENG Juan. PCSK9:a new therapeutic target for cardiovascular calcification?[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2024,32(9):798-804.

Copy

Article Metrics

Abstract:
PDF:
HTML:
Cited by:

History

Received:October 19,2023
Revised:November 16,2023
Adopted:
Online: September 30,2024
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code